Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Noggin (NOG) (Middle Region) Peptide

NOG Reactivity: Human Host: Synthetic BP, WB
Catalog No. ABIN980789
  • Target See all NOG products
    NOG (Noggin (NOG))
    Protein Region
    Middle Region
    Origin
    Human
    Source
    • 1
    Synthetic
    Application
    Blocking Peptide (BP), Western Blotting (WB)
    Sequence
    GGHYDPGFMA TSPPEDRPGG GGGAAGGAED LAELDQLLRQ RPSGAMPSEI
    Characteristics
    This is a synthetic peptide designed for use in combination with anti-NOG Antibody(ARP58773_P050),. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
    Purification
    Purified
  • Application Notes
    Each Investigator should determine their own optimal working dilution for specific applications.
    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
    Concentration
    1 mg/mL
    Buffer
    Final peptide concentration is 1 mg/mL in PBS.
    Handling Advice
    Avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target
    NOG (Noggin (NOG))
    Synonyms
    SYM1 Peptide, SYNS1 Peptide, nog-A Peptide, nog1 Peptide, noggin-1 Peptide, noggin Peptide, noggin Peptide, noggin L homeolog Peptide, noggin protein Peptide, NOG Peptide, Nog Peptide, nog.L Peptide, noggin Peptide
    Background
    The secreted polypeptide, encoded by this gene, binds and inactivates members of the transforming growth factor-beta (TGF-beta) superfamily signaling proteins, such as bone morphogenetic protein-4 (BMP4). By diffusing through extracellular matrices more efficiently than members of the TGF-beta superfamily, this protein may have a principal role in creating morphogenic gradients. The protein appears to have pleiotropic effect, both early in development as well as in later stages. It was originally isolated from Xenopus based on its ability to restore normal dorsal-ventral body axis in embryos that had been artificially ventralized by UV treatment. The results of the mouse knockout of the ortholog suggest that it is involved in numerous developmental processes, such as neural tube fusion and joint formation. Recently, several dominant human NOG mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) were identified, both SYM1 and SYNS1 have multiple joint fusion as their principal feature, and map to the same region (17q22) as this gene. All of these mutations altered evolutionarily conserved amino acid residues. The amino acid sequence of this human gene is highly homologous to that of Xenopus, rat and mouse.

    Alias Symbols: SYM1, SYNS1

    Protein Interaction Partner: BMP2,BMP4,BMP5,BMP7,BMP7,NOG

    Protein Size: 232
    Molecular Weight
    24 kDa
    Gene ID
    9241
    NCBI Accession
    NM_005450, NP_005441
    UniProt
    Q13253
You are here:
Support